morpholino(4-(o-tolyl)piperazin-1-yl)methanone | 1548115-18-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: morpholino(4-(o-tolyl)piperazin-1-yl)methanone
• 英文别名: [4-(2-Methylphenyl)piperazin-1-yl]-morpholin-4-ylmethanone
• CAS: 1548115-18-9
• 化学式: C₁₆H₂₃N₃O₂
• 分子量: 289.378
• InChiKey: LIQHJDJFKGOAGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  36
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-吗啉碳酰氯 在 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 18.5h， 生成 morpholino(4-(o-tolyl)piperazin-1-yl)methanone
  参考文献：
  名称：

  Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3)

  摘要：

  Inhibitors of the aldo-keto reductase enzyme AKR1C3 are of interest as potential drugs for leukemia and hormone-related cancers. A series of non-carboxylate morpholino(phenylpiperazin-1-yl)methanones were prepared by palladium-catalysed coupling of substituted phenyl or pyridyl bromides with the known morpholino(piperazin-1-yl)methanone, and shown to be potent (IC50 similar to 100 nM) and very isoform-selective inhibitors of AKR1C3. Lipophilic electron-withdrawing substituents on the phenyl ring were positive for activity, as was an H-bond acceptor on the other terminal ring, and the ketone moiety (as a urea) was essential. These structure-activity relationships are consistent with an X-ray structure of a representative compound bound in the AKR1C3 active site, which showed H-bonding between the carbonyl oxygen of the drug and Tyr55 and His117 in the 'oxyanion hole' of the enzyme, with the piperazine bridging unit providing the correct twist to allow the terminal benzene ring to occupy the lipophilic pocket and align with Phe311. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.12.050

文献信息

• AZOLECARBOXAMIDE DERIVATIVE
  申请人：Sugasawa Keizo

  公开号：US20090286766A1

  公开（公告）日：2009-11-19

  Provided is an agent for treating or preventing urinary frequency, urinary urgency and urinary, incontinence which are associated with overactive bladder, a lower urinary tract disease such as interstitial cystitis and chronic prostatitis accompanied by lower urinary tract pain, and various diseases accompanied by pain. A novel azolecarboxamide derivative in which an azole ring such as thioazole or oxazole is bonded to a benzene ring, pyridine ring or pyrimidine ring through carboxamide was confirmed to have a potent trkA receptor-inhibitory activity and found to be an agent for treating or preventing lower urinary tract disease and various diseases accompanied by pain, which is excellent in efficacy and safety, and thus the present invention was accomplished.

  提供了一种用于治疗或预防与过度活跃膀胱、下泌尿道疾病（如间质性膀胱炎和慢性前列腺炎伴随下泌尿道疼痛）以及伴随疼痛的各种疾病相关的尿频、尿急和尿失禁的药剂。一种新型的唑烷羧酰胺衍生物，其中唑环（如硫唑环或噁唑环）通过羧酰胺键连接到苯环、吡啶环或嘧啶环上，被证实具有强效的trkA受体抑制活性，并被发现是一种用于治疗或预防下泌尿道疾病和伴随疼痛的各种疾病的药剂，其疗效和安全性优异，因此本发明得以完成。
• US8163746B2
  申请人：——

  公开号：US8163746B2

  公开（公告）日：2012-04-24
• Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3)
  作者：Jack U. Flanagan、Graham J. Atwell、Daniel M. Heinrich、Darby G. Brooke、Shevan Silva、Laurent J.M. Rigoreau、Elisabeth Trivier、Andrew P. Turnbull、Tony Raynham、Stephen M.F. Jamieson、William A. Denny

  DOI：10.1016/j.bmc.2013.12.050

  日期：2014.2

  Inhibitors of the aldo-keto reductase enzyme AKR1C3 are of interest as potential drugs for leukemia and hormone-related cancers. A series of non-carboxylate morpholino(phenylpiperazin-1-yl)methanones were prepared by palladium-catalysed coupling of substituted phenyl or pyridyl bromides with the known morpholino(piperazin-1-yl)methanone, and shown to be potent (IC50 similar to 100 nM) and very isoform-selective inhibitors of AKR1C3. Lipophilic electron-withdrawing substituents on the phenyl ring were positive for activity, as was an H-bond acceptor on the other terminal ring, and the ketone moiety (as a urea) was essential. These structure-activity relationships are consistent with an X-ray structure of a representative compound bound in the AKR1C3 active site, which showed H-bonding between the carbonyl oxygen of the drug and Tyr55 and His117 in the 'oxyanion hole' of the enzyme, with the piperazine bridging unit providing the correct twist to allow the terminal benzene ring to occupy the lipophilic pocket and align with Phe311. (C) 2013 Elsevier Ltd. All rights reserved.